Education
About Us
Working with TipRanks
Follow Us
Holuka Eugene Myron Insider Profile
4 Followers
Holuka Eugene Myron, Director at Citius Pharmaceuticals, holds 300.00K shares in Citius Oncology (Ticker: CTOR), holds 2.37K shares in Citius Pharmaceuticals (Ticker: CTXR).
Holuka Eugene Myron has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Holuka Eugene Myron holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Holuka Eugene Myron
Holuka Eugene Myron's Trading History
Citius Pharmaceuticals
Aug 30, 2024
Director
Uninformative Buy
23.67
$2.79K
Citius Oncology
Sep 23, 2025
Director
Uninformative Buy
―
$609.00K
List of latest transactions for each holding click on a transaction to see Holuka Eugene Myron's performance on stock
You May Also Like
Holuka Eugene Myron insider profile FAQ
What is the percentage of profitable transactions made by Holuka Eugene Myron?
The percentage of profitable transactions made by Holuka Eugene Myron is ―.
What is the average return per transaction made by Holuka Eugene Myron?
The average return per transaction made by Holuka Eugene Myron is ―.
What stocks does Holuka Eugene Myron hold?
Holuka Eugene Myron holds: CTXR, CTOR stocks.
What was Holuka Eugene Myron’s latest transaction?
Holuka Eugene Myron latest transaction was an Uninformative Buy of ―.
What was Holuka Eugene Myron's most profitable transaction?
Holuka Eugene Myron’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Holuka Eugene Myron's role in Citius Pharmaceuticals?
Holuka Eugene Myron's role in Citius Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.